Clinical Trials Browser

Phase 1 × Interventional × aflutinib × Clear all

NCT05364073 2026-03-13

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04858958 2025-11-19

FAVOUR

Phase 1 Active not recruiting

NSCLC

NCT02973763 2025-04-03

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Phase 1 Terminated

NSCLC

NCT04958967 2025-03-14

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Phase 1 Withdrawn

NSCLC

NCT06868732 2025-03-11

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Phase 1 Not yet recruiting

Advanced Non-small Cell Lung Cancer